Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Sort descending Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Humira Adalimumab Psoriasis List with clinical criteria and/or conditions Complete
Humira Adalimumab Hidradenitis suppurativa Reimburse with clinical criteria and/or conditions Complete
Humira Adalimumab Ulcerative colitis Do not list at the submitted price Complete
Humira Adalimumab Arthritis, juvenile idiopathic List with clinical criteria and/or conditions Complete
Humira Adalimumab ulcerative colitis Withdrawn
Hepsera Adefovir dipivoxil Hepatitis B Do not list Complete
Hepsera Adefovir dipivoxil Hepatitis B List with clinical criteria and/or conditions Complete
Aduhelm aducanumab Alzheimer’s disease Withdrawn
Giotrif Afatinib Advanced or Metastatic Non-Small Cell Lung Cancer Reimburse Complete
Zaltrap Aflibercept Metastatic Colorectal Cancer Do not reimburse Complete